Computer-tailored drug dosing aims to tame Crohn's in kids
NCT ID NCT04974099
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tested whether a computer program that customizes infliximab doses based on blood tests can help children and young adults with Crohn's disease reach better drug levels than standard dosing. Only 6 participants were enrolled before the study was stopped early. The goal was to see if personalized dosing is feasible and safe, not to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- infliximab
- What this could lead to
- If successful, this could show that personalized dosing helps more patients reach optimal drug levels, potentially improving disease control.
- What could go wrong
- This was a small, terminated early study with only 6 participants, so results are very limited and may not apply broadly. The approach may not prove better than standard dosing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?